Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Status:
Active, not recruiting
Trial end date:
2022-10-07
Target enrollment:
Participant gender:
Summary
This study will determine if the combination of regorafenib and pembrolizumab is safe and
tolerated in patients with advanced liver cancer. In addition, the study will explore the
anti-tumor activity of this combination as well as potentially identifying blood and tissue
biomarkers associated with disease activity, status or response. The study will also
investigate how the drugs behave in your body